Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) EBIT (2023 - 2025)

Historic EBIT for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to -$22.8 million.

  • Metagenomi's EBIT fell 203.73% to -$22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.3 million, marking a year-over-year decrease of 428.94%. This contributed to the annual value of -$88.9 million for FY2024, which is 1326.12% down from last year.
  • Metagenomi's EBIT amounted to -$22.8 million in Q3 2025, which was down 203.73% from -$21.0 million recorded in Q2 2025.
  • Metagenomi's 5-year EBIT high stood at -$16.9 million for Q2 2024, and its period low was -$29.0 million during Q1 2024.
  • Moreover, its 3-year median value for EBIT was -$21.0 million (2025), whereas its average is -$21.7 million.
  • Data for Metagenomi's EBIT shows a peak YoY increase of 612.37% (in 2024) and a maximum YoY decrease of 6184.64% (in 2024) over the last 5 years.
  • Over the past 3 years, Metagenomi's EBIT (Quarter) stood at -$20.2 million in 2023, then fell by 2.11% to -$20.6 million in 2024, then dropped by 10.75% to -$22.8 million in 2025.
  • Its EBIT stands at -$22.8 million for Q3 2025, versus -$21.0 million for Q2 2025 and -$27.8 million for Q1 2025.